US Patent

US8071073 — Compositions comprising azelastine and methods of use thereof

Formulation · Assigned to Meda Pharmaceuticals Inc · Expires 2028-06-04 · 2y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions containing azelastine hydrochloride, including optional additional active agents and carriers to reduce post-nasal drip and bitter taste.

USPTO Abstract

The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance.

Drugs covered by this patent

Patent Metadata

Patent number
US8071073
Jurisdiction
US
Classification
Formulation
Expires
2028-06-04
Drug substance claim
No
Drug product claim
Yes
Assignee
Meda Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.